- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02049827
Evaluation of a Predictive Immunovirological Test Occurrence of BK Virus Nephropathy in Renal Transplant
Kidney transplantation is the treatment of choice for end stage renal disease (ESRD) improving the quantity and quality of life for dialysis patients. Although prolongation of graft survival in the short term by preventing the release is observed by immunosuppression (IS) powerful, the longer-term survival has not improved . Indeed, the IS can not only have a direct deleterious effect on the kidney transplant , but too weak IS can promote rejection, and too strong, promote the emergence of a viral disease polyomavirus BK ( BKV ) . BK nephropathy (BKVAN ) virus is accompanied by an irreversible impairment of the renal function , leading to a loss of the graft followed by a premature return to dialysis in at least 50 % of cases. Plasma BKV reactivation was observed mainly during the first year of transplantation in 15% of patients and complications annually BKVAN concern about 5 % of recipients . Currently , treatment options are very limited , only the decrease in IS shows a partially effective when care is early . There is no specific antiviral effective treatment of this disease . In addition, there is no way to predict which patients will develop BKV reactivation BKVAN despite lower tax.
The diagnosis of interstitial nephritis BKV based on the detection of viral DNA by PCR and plasma is confirmed by histological analysis of renal tissue . Plasma quantitative PCR ( qPCR) to measure the progression of the disease and therapeutic efficacy. Control of BKV viremia is the direct antiviral immune response quality based primarily on a very effective anti- T lymphocyte activity BKV reflection. In this context, the inhibition of lymphocyte activation induced by IS blocks the establishment of T-cell responses anti- BKV in most transplant, a very low presence of T lymphocytes is generally observed in these patients anti- BKV (LYT - BKV) blood .
Our preliminary studies have validated in vitro a sensitive test to measure the functionality of blood LYT - BKV. This test is used to evaluate the concentration and functionality of LYT - BKV present in small volume of blood by measuring their specific proliferation after stimulation with peptide cocktails BKV. Proof of concept of the feasibility of this test was established on a small series of samples and highlights significant differences in lymphocyte anti-BKV different patients.
Put to good use during the post-transplant follow-up, this type of test can provide the clinician with valuable data to assess the quality of anti- BKV T response compared to the intensity and type of IS treatment. Early identification of patients at risk of reactivation of BKV, or at risk of BKVAN if BKV viremia observed , would adapt the therapeutic response and monitoring arrangements at the fair. The objective of this project is to conduct a feasibility study to assess the relevance of post-transplant monitoring of anti- BKV T response of BKV viremic patients during the first year post- transplant. Immunological data will be analyzed in relation to virological data and bioclinical data.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nice, France, 06000
- Chu de Nice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Renal transplant > 12 months
- positive for BKV viremia
- immunosuppressive therapy including tacrolimus and mycophenolate
Exclusion Criteria:
- immunosuppressive therapy including cyclosporine and / or mTOR inhibitor
- Pregnant Women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Renal transplant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of BKV viral
Time Frame: at 6 months and 12 months
|
Quantitative Measurement of BKV viral load decline after IS.
Negativation sign healing, persistence is poor prognosis.
|
at 6 months and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
stability, decrease, increase of viremia
Time Frame: 4 weeks, 8 weeks, 12 weeks, 6 months and 1 year
|
The evolution of viremia (stability, decrease, increase) profile may also be considered to analyze the immunological data obtained.
|
4 weeks, 8 weeks, 12 weeks, 6 months and 1 year
|
Collaborators and Investigators
Investigators
- Study Director: Laetitia ALBANO, MD, Centre Hospitalier Universitaire de Nice
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 13-AOI-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplant
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
Queen Mary University of LondonRecruitingImmunosuppression | Renal Transplant Rejection | Renal Transplant Failure | Renal Transplant InfectionUnited Kingdom
-
PfizerCompletedRenal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft RecipientsUnited States, Australia, Germany, Italy, Spain, Brazil, Argentina
-
Alp SenerNot yet recruitingRenal Transplant | Kidney Transplant
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
Ha Young OhBaxter Healthcare CorporationUnknownAcute Rejection of Renal Transplant | Delayed Function of Renal Transplant | Primary Nonfunction of Renal TransplantKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...University of PittsburghRecruitingKidney Transplant | Renal Transplant RecipientsUnited States
-
Liverpool University Hospitals NHS Foundation TrustKidney Research United KingdomNot yet recruitingFrailty | Kidney Transplant Rejection | Renal Transplant | Diagnosis | Kidney Transplant; Complications | Kidney Transplant | Renal Transplant Failure | Transplant DysfunctionUnited Kingdom
-
Jeffrey Veale, MDOneLegacy FoundationRecruitingTolerance | Renal Transplant Rejection | Kidney TransplantUnited States
-
University of AarhusCompletedRenal Transplant Candidate for Right Kidney | Renal Transplant Candidate for Left KidneyDenmark
Clinical Trials on participation in the study
-
University of AarhusAarhus County, DenmarkCompleted
-
Frederiksberg University HospitalCompletedMusculoskeletal Diseases | Osteoarthritis, Knee | Illness PerceptionsDenmark
-
Wonryeon ChoRecruitingHealthy Elderly | YogaKorea, Republic of
-
Sahlgrenska University Hospital, SwedenHögskolan VästCompleted
-
Rune Zahl-OlsenCompleted
-
University of Castilla-La ManchaRecruitingPatient Participation | Family Research | Public and Patient Involvement | ParticipationSpain
-
University of California, San FranciscoCompletedPhysical InactivityUnited States
-
Lady Davis InstituteRecruitingEngagement, Patient | Family Members | Health Care ProvidersCanada
-
Baqiyatallah Medical Sciences UniversityShahid Beheshti University; Tehran University of Medical SciencesCompletedVentilator-associated Pneumonia
-
US Department of Veterans AffairsCompletedMuscle WeaknessUnited States